Drug Interaction, Pharmacokinetic, Pharmacodynamic
Conditions
Brief summary
Cohort 1 To evaluate the pharmacokinetic interactions of CJ-12420 after multiple oral doses of CJ-12420 given alone or in combination with amoxicillin/clarithromycin in healthy subjects. Cohort 2 To evaluate the pharmacodynamic profiles of CJ-12420 after multiple oral doses of CJ-12420 in combination with amoxicillin/clarithromycin in healthy subjects as compared to an active control group, i.e., pantoprazole in combination with amoxicillin/clarithromycin.
Detailed description
To evaluate the pharmacokinetic the drug-drug interaction of CJ-12420 and amoxicillin/clarithromycin and investigate the pharmacodynamic of co-administration of CJ-12420 and amoxicillin and clarithromycin.
Interventions
DRUGCLR 500mg
Cohort 1: bid for 5 days Cohort 2: bid for 7 days
DRUGCJ-12420 100mg
Cohort 1: bid for 5 days Cohort 2: bid for 7 days
DRUGCJ-12420 50mg
Cohort 2: bid for 7 days
DRUGAMX 1g
Cohort 1: bid for 5 days Cohort 2: bid for 7 days
Cohort 2: bid for 7 days
Sponsors
HK inno.N Corporation
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
1. Healthy male volunteers aged ≥19 and ≤45 years at screening; 2. No congenital or chronic disease, and no morbid symptoms or findings on screening tests; 3. Body mass index (BMI) ≥18.5 and ≤28 kg/m2; 4. Considered eligible based on medical examinations (including interview, vital signs, 12-lead ECG, physical exam and laboratory tests) which are set and performed in accordance with the nature of investigational product by the investigator; 5. Voluntary consent to participate in the study after being fully informed of purpose and procedures of the study, and profiles of investigational product prior to the participation; 6. For Cohort 2, positive on 13C urea breath test.
Exclusion criteria
1. Medical history 1. History or current evidence for diseases considered clinically relevant by the investigator including hepatic, renal, gastrointestinal, respiratory, musculoskeletal, endocrine, neurologic, hemato-oncological, urinary, or cardiovascular (including cardiac arrhythmia) diseases; 2. History of gastrointestinal diseases (such as gastritis, gastrodynia, gastroesophageal reflux disease, Crohn's disease and ulcer) or abdominal surgery (except for simple appendectomy or herniotomy) which are considered to have potential effect on drug absorption by the investigator; 3. For Cohort 2, previous treatment failure for H. pylori eradication. 2. Laboratory tests and ECG 1. AST or ALT ≥ 1.25 x upper limit of normal (ULN); 2. Total bilirubin ≥ 1.5 x ULN; 3. eGFR calculated by CKD-EPI formula \< 80 mL/min; 4. Any clinically relevant ECG abnormalities. 3. Allergy and drug abuse 1. History of hypersensitivity to drugs containing investigational products (penicillins, cephems, macrolides, pantoprazole and benzimidazole) and other drugs (including aspirin and antibiotics); 2. History of drug abuse or positive on drug screening test. 4. Drug/dietary restrictions 1. Medications (including herbal supplements) or abnormal diet (e.g., grapefruit juice \> 1 L/day, excessive garlic, broccoli, kale, etc.) which may have effect on absorption, distribution, metabolism and excretion of investigational products within 28 days prior to the first study dose; 2. Use of prescription drugs, over-the-counter drugs (OTCs) or vitamins within 10 days prior to the first study dose; 3. Participating in other study and receive investigational product within 3 months prior to the first study dose. 5. Blood donation and transfusion 1. Whole blood donation within 60 days prior to the first study dose; 2. Donation of blood components or transfusion within 30 days prior to the first study dose. 6. Pregnancy and contraception 1. Pregnant or breast-feeding; 2. Subject or his partner's inability to use of medically qualifying dual-contraceptive methods or medically acceptable contraception (including intrauterine device with established pregnancy failure rate, barrier methods with spermicide, vasectomy, tubectomy, tubal ligation and hysterectomy) from screening to 30 days of the last dose of investigational product. 7. Others 1. Heavy use of alcohol (average alcohol intake ≥30 g/day) or positive on alcohol test; 2. Heavy smoker (\>10 cigarettes/day); 3. Caffeine intake \> 400 mg/day; 4. Any clinically relevant findings considered inappropriate for study participation at the discretion of the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Peak Plasma Concentration (Cmax) of CJ-12420, clarithromycin and amoxicillin | Up to 120 hours |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time of maximum observed concentraion(tmax) of CJ-12420, clarithromycin and amoxicillin | Up to 120 hours | — |
| Half life(t1/2) of CJ-12420, clarithromycin and amoxicillin | Up to 120 hours | — |
| Oral clearance at steady state(CLss/F) of CJ-12420, clarithromycin and amoxicillin | Up to 120 hours | — |
| Apparent volume of distribution at steady state(Vdss/F) of CJ-12420, clarithromycin and amoxicillin | Up to 120 hours | — |
| Area under the plasma concentration versus time curve (AUC) of CJ-12420, clarithromycin and amoxicillin | Up to 120 hours | — |
| Time at pH > 3 (%) | Day -1, Day 1, Day 7 up to 24 hours | the percent of time the pH as data from the pH probe monitoring |
| Time at pH > 4 (%) | Day -1, Day 1, Day 7 up to 24 hours | the percent of time the pH as data from the pH probe monitoring |
| Time at pH > 6 (%) | Day -1, Day 1, Day 7 up to 24 hours | the percent of time the pH as data from the pH probe monitoring |
| median pH | Up to 24 hours | Data from the pH probe monitoring |
Countries
South Korea
Outcome results
None listed